Xenon Pharmaceuticals is a clinical-stage biopharma focused on neurology and ion-channel biology. Its lead program, azetukalner (XEN1101), is an oral potassium-channel modulator in late-stage development for epilepsy and other neurological indications. The company builds a pipeline of precision neuroscience candidates aimed at disorders with significant unmet need rather than commercial primary-care products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -84.7 | — |
| Q3 2025 | 0 | — | -90.9 | — |
| Q4 2025 | 0 | — | -105.3 | — |
| Q1 2026 | 0 | — | -102.3 | — |
| Q2 2026 | 0 | — | -110.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TowneBank (TOWN), Star Bulk Carriers Corp. (SBLK), Freshpet, Inc. (FRPT), Viking Therapeutics, Inc. (VKTX), Simmons First National Corporation (SFNC), Tarsus Pharmaceuticals, Inc. (TARS)